van Mackelenbergh MT, et al. – The focus of the presented study was to examine progesterone receptor (PgR) expression as a predictive factor for response to neoadjuvant therapy and long-term outcome. Findings revealed that estrogen receptor (ER)-positive/PgR-negative breast carcinomas were related to higher response but also worse long-term outcome after neoadjuvant therapy. The results showed that PgR negativity was an independent predictive factor for pathologic complete response (pCR) after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.